A 2019 dose escalation trial published in the Journal of Clinical Oncology by Cuneo et al. evaluated the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.

Authors

• Person: Not available Organization: Nature
  Perspectives on cancer therapy—synthetic lethal precision medicine ...

Sources

• Perspectives on cancer therapy—synthetic lethal precision medicine ... www.nature.com Nature via serper

Referenced by nodes (1)

• Adavosertib concept